Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1529-1543

Bentham Science Publishers

Access to resources Recommend Favorite

3D-QSAR Studies on Isocoumarin-based Urokinase-type Plasminogen Activator (uPA) Inhibitors Employing Linear and Non-linear Regression Analysis Methods

By  

Letters in Drug Design & Discovery, Vol. 9, Iss. 9, 2012-11 ,pp. : 874-880

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy

By Frankenne F.   Noel A.   Bajou K.   Sounni N.   Goffin F.   Masson V.   Munaut C.   Remacle A.   Foidart J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 3, 1999-09 ,pp. : 469-481

Informa Healthcare

Access to resources Recommend Favorite

Dormant Circulating Tumor Cells in Prostate Cancer: Therapeutic, Clinical and Biological Implications

By  

Current Drug Targets, Vol. 17, Iss. 6, 2016-05 ,pp. : 693-701

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer

By  

Current Drug Targets, Vol. 11, Iss. 6, 2010-06 ,pp. : 733-744

Bentham Science Publishers

Access to resources Recommend Favorite